Brief: Nanexa Comments On News About License On Long-Acting Technology Platform
Nov 5 (Reuters) - Nanexa AB NANEXA.ST :
* COMMENTS ON NEWS ABOUT THE LICENSE ON A LONG-ACTING
TECHNOLOGY
PLATFORM PUBLISHED THIS MONDAY
* IT IS CLEAR THAT WE HAVE SEVERAL COMPANIES INTERESTED IN
PHARMASHELL TECHNOLOGY FOR USE TO DEVELOP LONG-ACTING GLP-1
PRODUCTS AND OTHERS
Source text: ID:nMFN8snFn
Further company coverage: NANEXA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nanexa AB
See all newsNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Brief: Forge Nano And Nanexa To Develop Gmp-Compatible Ald Manufacturing Equipment
Brief: Nanexa Q2 Revenue Amounted To SEK 1.7 Million
Sweden's Nanexa Q1 revenue falls, loss widens